UW Student Christoph Geisler and his mentor UW Molecular Biology Professor Don Jarvis created GlycoBac to commercialize certain aspects of Dr. Jarvis' research, which involves the use of genetically engineered insect cells for manufacturing vaccines, diagnostics or therapeutics for use in human and veterinary medicine.
The UW-owned technology will be used by the Laramie-based company, GlycoBac LLC, to create new genetically engineered insect cell lines optimized for this purpose. Those lines will then be broadly offered throughout the biotechnology community as a new biologics manufacturing platform.
Biologics are a class of protein-based drugs that include vaccines, diagnostic testing reagents, and therapeutics, such as high-value cancer-fighting antibodies and proteins that can be used to treat genetic diseases, including diabetes and anemia.
GlycoBac LLC is also a winner of the 2011 John P. Ellbogen $30K Entrepreneurship Competition.